OverviewChartNewsTraderScreen

UC WAR. CALL 12/25 ZEG/  DE000HD7TME9  /

gettex
2024-08-23  9:46:12 PM Chg.+0.0500 Bid9:59:08 PM Ask9:59:08 PM Underlying Strike price Expiration date Option type
2.0800EUR +2.46% 2.0500
Bid Size: 3,000		 2.1100
Ask Size: 3,000		 Astrazeneca PLC ORD ... 130.00 GBP 2025-12-17 Call
GlobeNewswire 08-12 Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune...
GlobeNewswire 08-08 Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets...
GlobeNewswire 08-06 Cellectis Provides Financial Results for the Second Quarter 2024
GlobeNewswire 08-06 FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
TeleTrader 07-25 AstraZeneca's Q2 revenue up by 13% to $12.94B
GlobeNewswire 07-15 AstraZeneca Closes Acquisition of Amolyt Pharma
GlobeNewswire 06-26 As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire 06-18 Mika Health Collaborates with AstraZeneca and Daiichi Sankyo to Deliver AI-Enabled Mobile Support to...
GlobeNewswire 06-18 Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire 06-13 Rheumatologists' Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
GlobeNewswire 05-28 Cellectis Reports Financial Results for First Quarter 2024
TeleTrader 05-21 AstraZeneca to deliver $80B total revenue by 2030
TeleTrader 05-20 AstraZeneca to build $1.5B plant in Singapore
GlobeNewswire 05-08 Annual NMDP Gala in New York Raises More Than $560,000, Enabling More Patients to Receive Life-Savin...
GlobeNewswire 05-06 FibroGen Reports First Quarter 2024 Financial Results
GlobeNewswire 05-06 Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
GlobeNewswire 05-02 Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...
GlobeNewswire 04-29 Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
TeleTrader 04-25 Europe opens mostly down after corporate earnings
TeleTrader 04-25 AstraZeneca Q1 revenue jumps 19% to $12.7B
GlobeNewswire 03-28 HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Pati...
TeleTrader 03-19 AstraZeneca to acquire Fusion for $2 billion
GlobeNewswire 03-18 AAFA Statement in Response to AstraZeneca Asthma Inhaler Cost Announcement
TeleTrader 03-14 AstraZeneca to acquire Amolyt Pharma for $1.05B
GlobeNewswire 03-14 Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca